



BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,
Palace Road, Bangalore - 560 052, India.

25.09.2025

To,
The Manager-Listing
BSE Limited
Mumbai.

To
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

Dear Sir,

Sub: Brief Proceedings of 38th Annual General Meeting ('AGM') held on 25.9.2025.

Ref : Scrip code 524824 for BSE and BALPHARMA for NSE.

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting to the exchange the business transacted at the 38th Annual General Meeting of the Company conducted through audio visual means, on 25.09.2025.

All the members of the Board of Directors including the Chairman of the Audit Committee, Nomination and Remuneration Committee, Stakeholder Relationship Committee were present at the AGM. Representatives of Statutory Auditors, Secretarial Auditor and Scrutinizer were also present.

Mr. Shailesh Siroya, Managing Director was elected as Chairman and he chaired the proceedings of the meeting with requisite quorum.

Chairman provided a brief overview on the performance of the Company during the financial year 2024.25 and later invited questions and/or clarifications from the members attending the meeting through audio visual means. Queries from the shareholders received through e-mail were also answered suitably by the Chairman.

The following is the business transacted at the meeting as per the meeting agenda circulated.



Registered Office : Plot No. 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099, Karnataka, INDIA.

Ph: +91 80 41570811/813.

CIN # L85110KA1987PLC008368

www.balpharma.com



Ordinary Business:

1. Received, considered and adopted the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31,2025, the Statement of Profit and Loss for the financial year ended as on that date and the Cash Flow Statement together with the Reports of the Board of Directors and the Auditors thereon.
2. Declared dividend of Re.1.20/- per Equity Share of Rs.10/- each.
3. Appointed Mr. Himesh Virupakshya (DIN # 08554422) as Whole Time Director of the Company, who was retiring by rotation and being eligible, offered himself for reappointment.

Special Business:

4. Appointed Mr.Parameshwar G Bhat (M.No.11004) Practising Company Secretary as Secretarial Auditor of the Company for a term of 5 years.
5. Re-appointed Mr.Jatish Sheth (00581963) as Independent Director of the Company for a second term of 5 years.
6. Ratified the remuneration payable to the Cost auditors for the financial year 2025.26.
7. Approved the 'Bal Pharma Ltd – Employees Stock Option Plan -2025'

Mr.Prameshwar G Bhat, practising Company Secretary was appointed as the scrutinizer for the e-voting and the results of e-voting will be announced after receipt of Scrutinizer's Report.

The e-voting results will be submitted to the exchanges as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and also uploaded on our website.





BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,
Palace Road, Bangalore - 560 052, India.

Page-3

The 38th Annual General Meeting commenced at 11.30 AM as scheduled and concluded at 12.25 PM on 25.09.2025.

Please take this intimation on record.

Thanking you

For Bal Pharma Limited


Shailesh Siroya
Managing Director.



SHAILESH SIROYA

Digitally signed by SHAILESH SIROYA
DN: cn=IN, o=Personal,
2.5.4.20=84ab941967c90d592e2f1174fc0
c3d1e2a28f54cc3b61e26f9cd3ff67d54c
4a, postalCode=560020, st=Karnataka,
serialNumber=0f3b0eb66c935e3f2972d9
a58c18f3254e937f84f1fce82bf0fe2fb061
000bc5, cn=SHAILESH SIROYA
Date: 2025.09.25 15:28:53 +05'30'